XNAS · Healthcare · Biotechnology
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.54 | -0.46 | +14.81% | $99.6M | ✅ Beat | -1.14% | +2.86% | -15.91% |
| 2026-02-26 | Q4 2025 | -0.43 | -0.46 | -6.98% | $127.6M | ❌ Miss | -0.98% | -1.98% | -8.58% |
| 2025-11-06 |
| Q3 2025 |
| -0.29 |
| -0.33 |
| -13.79% |
| $116.1M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -0.40 | -0.37 | +7.50% | $110.0M | ✅ Beat | -2.12% | +2.49% | -9.74% |
| 2025-02-27 | Q4 2024 | -0.07 | -0.80 | -1042.86% | $109.1M | ❌ Miss | +0.76% | +2.94% | +5.12% |
| 2024-11-12 | Q3 2024 | -0.78 | -0.42 | +46.15% | $102.3M | ✅ Beat | +3.42% | -9.70% | -7.73% |
| 2024-08-06 | Q2 2024 | -0.70 | -0.82 | -17.14% | $100.5M | ❌ Miss | -8.06% | -10.27% | +8.45% |
| 2024-05-08 | Q1 2024 | -0.92 | -0.55 | +40.22% | $87.1M | ✅ Beat | +26.80% | +25.83% | +20.70% |
Showing last 8 quarters.